Fuchs DystrophySymptoms, Doctors, Treatments, Advances & More
Learn About Fuchs Dystrophy
Fuchs (pronounced "fooks") dystrophy is an eye disease in which cells lining the inner surface of the cornea slowly start to die off. The disease most often affects both eyes.
Fuchs' dystrophy; Fuchs' endothelial dystrophy; Fuchs' corneal dystrophy
Fuchs dystrophy can be inherited, which means it can be passed down from parents to children. If either of your parents has the disease, you have a 50% chance of developing the condition.
However, the condition may also occur in people without a known family history of the disease.
Fuchs dystrophy is more common in women than in men. Vision problems do not appear before age 50 years in most cases. However, a health care provider may be able to see signs of the disease in affected people by their 30s or 40s.
Fuchs dystrophy affects the thin layer of cells (endothelium) that lines the back part of the cornea. These cells help pump excess fluid out of the cornea. As more and more cells are lost, fluid begins to build up in the cornea, causing swelling and a cloudy cornea. Another reason for visual loss is the development of gutatta, which are little bumps that develop in the endothelium. These bumps can cause glare by breaking up the incoming light rays.
At first, fluid may build up only during sleep, when the eye is closed. As the disease gets worse, small blisters may form. The blisters get bigger and may eventually break. This causes eye pain. Fuchs dystrophy can also cause the shape of the cornea to change, leading to more vision problems.
Symptoms may include:
- Eye pain
- Eye sensitivity to light and glare
- Foggy or blurred vision, at first only in the mornings
- Seeing colored halos around lights
- Worsening vision throughout the day
Eye drops or ointments that draw fluid out of the cornea are used to relieve symptoms of Fuchs dystrophy.
If painful sores develop on the cornea, soft contact lenses or surgery to create flaps over the sores may help reduce pain.
The only cure for Fuchs dystrophy is a corneal transplant.
Until recently, the most common type of corneal transplant was penetrating keratoplasty. During this procedure, a small round piece of the cornea is removed, leaving an opening in the front of the eye. A matching piece of cornea from a human donor is then sewn into the opening in the front of the eye.
A newer technique called endothelial keratoplasty (DSEK, DSAEK, or DMEK) has become the preferred option for people with Fuchs dystrophy. In this procedure, only the inner layers of the cornea are replaced, instead of all the layers. This leads to a faster recovery and fewer complications. Stitches are most often not needed.
For people with Fuchs dystrophy that have mostly guttata and not much swelling, stripping off a small central disk of the endothelium containing the guttata can be helpful. In this method, DWEK, transplanting new endothelium, as would be done in DSEK, DSAEK or DMEK, is not necessary.
Johns Hopkins Community Physicians - Water's Edge
Allen Eghrari is an Ophthalmologist practicing medicine in Belcamp, Maryland. Dr. Eghrari is rated as an Elite provider by MediFind in the treatment of Fuchs Dystrophy. He is also highly rated in 9 other conditions, according to our data. His clinical expertise encompasses Fuchs Dystrophy, Macular Corneal Dystrophy Type 1, Ebola Virus Disease, Corneal Transplant, and Cataract Removal. Dr. Eghrari is board certified in American Board Of Ophthalmology. Dr. Eghrari is currently accepting new patients.
The Johns Hopkins Hospital
John Gottsch is an Ophthalmologist practicing medicine in Baltimore, Maryland. Dr. Gottsch is rated as an Elite provider by MediFind in the treatment of Fuchs Dystrophy. He is also highly rated in 3 other conditions, according to our data. His clinical expertise encompasses Macular Corneal Dystrophy Type 1, Fuchs Dystrophy, Corneal Dystrophy and Perceptive Deafness, Cataract, and Corneal Transplant. Dr. Gottsch is board certified in American Board Of Ophthalmology. Dr. Gottsch is currently accepting new patients.
Kellogg Eye Center
Shahzad Mian is an Ophthalmologist practicing medicine in Ann Arbor, Michigan. Dr. Mian is rated as an Elite provider by MediFind in the treatment of Fuchs Dystrophy. He is also highly rated in 42 other conditions, according to our data. His clinical expertise encompasses Interstitial Keratitis, Cataract, Fuchs Dystrophy, Corneal Transplant, and Cataract Removal. Dr. Mian is board certified in Ophthalmology. Dr. Mian is currently accepting new patients.
Fuchs dystrophy gets worse over time. Without a corneal transplant, a person with severe Fuchs dystrophy may become blind or have severe pain and very reduced vision.
Mild cases of Fuchs dystrophy often worsen after cataract surgery. A cataract surgeon will evaluate this risk and may modify the technique or the timing of your cataract surgery.
Contact your provider if you have:
- Eye pain
- Eye sensitivity to light
- The feeling that something is in your eye when there is nothing there
- Vision problems such as seeing halos or cloudy vision
- Worsening vision
There is no known prevention. Avoiding cataract surgery or taking special precautions during cataract surgery may delay the need for a corneal transplant.
Summary: This protocol will investigate whether topical application of N-acetyl cysteine (NAC) eye drops decreases oxidative stress and confers cytoprotection in patients with FECD.
Summary: Descemet Endothelial Thickness Comparison Trial (DETECT) II is a multi-center, outcome assessor-masked, placebo-controlled clinical trial randomizing 60 patients with Fuchs endothelial dystrophy to DMEK versus Descemet Stripping Only (DSO) with adjunctive Ripasudil.
Published Date: August 05, 2024
Published By: Franklin W. Lusby, MD, Ophthalmologist, Lusby Vision Institute, La Jolla, CA. Also reviewed by David C. Dugdale, MD, Medical Director, Brenda Conaway, Editorial Director, and the A.D.A.M. Editorial team.
Altamirano F, Ortiz-Morales G, O'Connor-Cordova MA, Sancén-Herrera JP, Zavala J, Valdez-Garcia JE. Fuchs endothelial corneal dystrophy: an updated review. Int Ophthalmol. 2024;44(1):61. PMID: 38345780 pubmed.ncbi.nlm.nih.gov/38345780/.
Castellucci M, Novara C, Casuccio A, et al. Bilateral ultrathin descemet's stripping automated endothelial keratoplasty vs. bilateral penetrating keratoplasty in Fuchs' dystrophy: corneal higher-order aberrations, contrast sensitivity and quality of life. Medicina (Kaunas). 2021;57(2):133. PMID: 33546152 pubmed.ncbi.nlm.nih.gov/33546152/.
Romano V, Passaro ML, Bachmann B, Baydoun L, Ni Dhubhghaill S, Dickman M, Levis HJ, Parekh M, Rodriguez-Calvo-De-Mora M, Costagliola C, Virgili G. Combined or sequential DMEK in cases of cataract and Fuchs endothelial corneal dystrophy—A systematic review and meta-analysis. Acta Ophthalmologica. 2024 Feb;102(1):e22-30. PMID: 37155336 pubmed.ncbi.nlm.nih.gov/37155336/.
Rosado-Adames N, Afshari NA. Diseases of the corneal endothelium. In: Yanoff M, Duker JS, eds. Ophthalmology. 6th ed. Philadelphia, PA: Elsevier; 2023:chap 4.21.
Vieira R, Castro C, Coelho J, Mesquita Neves M, Gomes M, Oliveira L. Descemet stripping without endothelial keratoplasty in early-stage central fuchs endothelial dystrophy: long-term results. Cornea. 2023;42(8):980-985. PMID: 36731082 pubmed.ncbi.nlm.nih.gov/36731082/.